Winrow, C.J., Gotter, A.L., Cox, C.D., Doran, S.M., Tannenbaum, P.L., Breslin, M.J., … Renger, J.J. (2011). Promotion of Sleep by Suvorexant — A Novel Dual Orexin Receptor Antagonist. Journal of Neurogenetics 25(1–2): 52–61.
http://dx.doi.org/10.3109/01677063.2011.566953.
The authors would like to correct the legend of Figure 3 in their published article to more clearly cite their earlier work in the panel within Figure 3 showing dose dependency. The authors propose the replacement of the figure legend as follows:
Figure 3. Suvorexant dose-dependently promotes sleep in rat EEG studies. Average duration (and SEM) per 30-minute interval in each of four sleep/wake states across 7 days of once-daily oral dosing with Suvorexant at 10 and 100 mg/kg/day are compared to 30 mg/kg/day (Cox et al., 2010). Time spent in active wake (AW), light sleep (LS), slow-wave sleep I/II (SWS I/II) and REM sleep (REM) is indicated. Dark bars in x -axis represent lights-off period with time of dosing indicated by an arrowhead on each graph. Average time spent in AW, LS, SWS, and REM sleep during 30-minute analysis intervals in response to vehicle treatment (closed circles) versus 10 mg/kg/day Suvorexant (open circles; left column), 30 mg/kg/day Suvorexant (open circles; middle column; Cox et al., 2010), and 100 mg/kg/day Suvorexant (open circles; right column). Analysis was carried out for 16 hours starting at lights off. Values are mean ± SEM (short, medium, and long tic marks represent p ≤ .05, ≤ .01, ≤ .001; linear mixed effects model for repeated measures), with time points exhibiting significant differences from vehicle highlighted. All studies run as a balanced crossover design (n = 8 rats) with 7 sequential days of dosing (56 nights/condition total), the average of each condition plotted for 10 hours.